Technology
Source of new products for the pharmaceutical industry
Devonian Health Group Inc.’s technology is based on a broad platform resulting from more than 20 years of research. This platform provides a unique water-based process for the extraction, purification, stabilization, and formulation of molecular complexes as Active Ingredients (AIs): the Supra Molecular Complexes Extraction and Stabilization Technology (“SUPREX™”).
The SUPREX™ technology is protected by an extensive intellectual property portfolio. Each Active Ingredient (AI) has the potential to target multiple diseases, making it a strong therapeutic platform.
Thykamine™ is the first drug derived from this platform. Its anti-inflammatory, antioxidant, and immunomodulatory activities have been demonstrated in several preclinical studies (in vitro and in vivo pharmacological studies; pharmacological and toxicological safety studies), as well as in a phase 1 clinical trial in healthy volunteers and a phase 2a “proof-of-concept” clinical trial in patients with mild to moderate distal ulcerative colitis.
We completed a Phase 2a, 2-week, randomized, double-blind, placebo-controlled, dose-ranging study evaluating the safety, tolerability, and exploratory efficacy of Thykamine™ rectal enema (250, 500, and 1000 mg OD) in patients with mild-to-moderate distal ulcerative colitis. In addition to safety, the study assessed clinical response and changes in established biomarkers of inflammation (CRP, hsCRP, ESR, FC, and FL), along with exploratory biomarkers measured in serum, plasma, urine, and biopsy tissue.
Despite the short treatment duration, Thykamine™ produced statistically significant reductions in fecal lactoferrin and marked, though non-significant, reductions in fecal calprotectin. It also induced pronounced decreases in CRP and hsCRP and modest reductions in ESR, with consistent trends favoring Thykamine™ over placebo. Clinically, Thykamine™ significantly improved rectal bleeding and showed favorable trends for stool frequency/diarrhea and abdominal pain, supported by improvements in the bowel symptoms dimension of the IBDQ. Combined with its excellent safety profile, these biomarker and clinical findings demonstrate clear biological activity and support the therapeutic potential of Thykamine™ in distal UC.
Devonian Health Group Inc. has also completed a phase 2 clinical trial in adults with mild-to-moderate atopic dermatitis using Thykamine™ formulated as a cream. Thykamine™ monotherapy achieved positive results by meeting the study’s primary endpoint with statistical significance, delivering a significant improvement in skin clearance as determined by the Investigator Global Assessment (IGA). The trial also demonstrated statistically significant results on secondary endpoints including Body Surface Area (BSA), pruritus, POEM, and Quality of Life. Thykamine™ was well tolerated, with a safety profile consistent with prior studies. The efficacy and safety profile support advancement into Phase 3 in the adult population and the initiation of a program in pediatric patients with mild-to-moderate atopic dermatitis.
To date, all data support the potential use of Thykamine™ as a therapeutic platform targeting several inflammatory diseases.
While the development of prescription drugs remains its core business, Devonian Health Group Inc. is also engaged in the development of high-value derma-cosmeceutical products as part of a secondary strategy to generate short-term revenues and optimize manufacturing efficiency.
Devonian Health Group Inc. also owns a state-of-the-art pharmaceutical facility.